The article reviews High Damages or Mere Refunds? Unconscionability and Failure of Essential Purpose in Contracts for Defective Hemp Seed published by Jacob Mohr in the Journal of Agricultural Law. (2019)

This article reviews Cheech and Chong Go to Court: Legal Challenges to California’s Prohibition of Hemp in Food Products by Jordan Paraise published in INDIANA INT’L & COMP. LAW REVIEW [Vol. 35:283] ($34.95)

This article reviews: Darcangelo, D. Redefining Injury: RICO, Employment Loss, and Corporate Accountability in Medical Marijuana Inc. v. Horn. (2025) doi:10.2139/ssrn.5286974.

This article discusses: Legal Risk Exposure Heightens Uncertainty in Developing U.S. Hemp Markets by Skorbiansky, Thornsbury and Camp, published in Choices (Quarter 2021) from the Agricultural & Applied Economics Association.

Reviewed in this article: Pittman et. al. The Rise of Hemp Litigation and the Primary Jurisdiction Doctrine. The Judges' Journal; Chicago Vol. 60, Iss. 1, (Winter 2021): 37-40.

Crossword puzzle about vapes

Please enjoy this crossword puzzle on appetite and hormone research.

A fun crossword puzzle about cannabis.

Cannabinoid Hyperemesis Syndrome (CHS) is a paradoxical condition causing severe nausea, vomiting, and abdominal pain linked to cannabis use, affecting up to 2.75 million Americans. Often misdiagnosed, CHS requires greater awareness among healthcare providers. The article explores its history, potential causes like genetic predisposition and receptor sensitivity, and treatment strategies such as abstinence and targeted therapies. Advancing diagnosis and research is essential to improving patient care and outcomes.

An FAQ for 2024 dedicated to the topic of Cannabinoid Hyperemesis Syndrome.

An exploration into the upscaling of hemp products in culinary delights.

If you’re someone who times the use of CBD versus THC—say, taking CBD in the morning and THC later in the afternoon—research shows that delayed consumption patterns can significantly alter the experience.

Coverage of contamination and laboratory issues in the USA, featuring statements from leading analytical chemists.

A short analysis of WSJ’s investigation into contamination in regulated cannabis products.

Research poster overview from EULAR 2024 conference regarding data collection and educational interventions for health care practitioners.

A comparison of cannabis, psilocybin and other substances from an FDA database.

(5 minutes) There may be millions of possible cannabis products formulations and varieties, which far exceeds the number of approved pharmaceutical drugs and any other known product category.

(3 min read) Brief commentary on the documents used for the recommendation regarding the rescheduling of cannabis (aka marijuana).

A commentary on Marcotte, T. D. et al. Driving Performance and Cannabis Users’ Perception of Safety. JAMA Psychiatry 79, 1–9 (2022). Phil Molloy, MD, is a contributor to this blog post. Be sure to check out our journal club discussion on this topic under live events at https://www.prc-trials-plus.com.

A commentary on Uthayakumaran, K., Sunil, M. & Ratcliffe, E. M. Evaluating the Role of the Endocannabinoid System in Axon Guidance: A Literature Review. Cannabis Cannabinoid Res.(2024) doi:10.1089/can.2023.0138